Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
10:07am, Wednesday, 05'th Nov 2025
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs
09:20am, Wednesday, 05'th Nov 2025
Novo Nordisk CEO Mike Doustdar joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's bid for obesity biotech company Metsera, negotiations with the Trump administration
Watch CNBC's full interview with Novo Nordisk CEO Mike Doustdar
08:28am, Wednesday, 05'th Nov 2025
Mike Doustdar, new CEO of Ozempic maker, Novo Nordisk discusses his strategy for the future of the company.
Novo Nordisk's obesity pill shows cardiovascular benefits, comparable efficacy to injection
08:17am, Wednesday, 05'th Nov 2025
Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar control and reduced cardiovascular risk factors, bolstering the Danish drugmake
White House speaking with Novo Nordisk, Eli Lilly about selling some obesity drugs for $149/mo: WSJ
07:13am, Wednesday, 05'th Nov 2025
CNBC's Andrew Ross Sorkin reports on the latest news.
Novo Nordisk Cuts Growth Outlook as Weight-Loss Drug Pressures Rise
06:47am, Wednesday, 05'th Nov 2025
Novo Nordisk (NVO, Financials) trimmed its full-year outlook after reporting quarterly results that showed continued demand for its weight-loss drugs but growin
Novo Nordisk says its head of manufacturing is stepping down
05:48am, Wednesday, 05'th Nov 2025
Wegovy maker Novo Nordisk said on Wednesday that its executive vice president in charge of manufacturing was stepping down.
Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera
05:42am, Wednesday, 05'th Nov 2025
Management lowers full-year guidance, warns about competition, launches bid for Metsera.
Novo Nordisk CEO: Confident we will close Metsera deal
05:39am, Wednesday, 05'th Nov 2025
Novo Nordisk CEO Mike Doustdar tells CNBC he expects to close the company's takeover offer for Metsera. This as the company finds itself in a bidding war with Pfizer for U.S. biotech firm.
Novo Nordisk accepts Ozempic, Wegovy and Rybelsus prices in US Medicare negotiations
03:51am, Wednesday, 05'th Nov 2025
Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes and obesity medicines Ozempic, Wegovy and Rybelsus, which will become effect
Novo Nordisk cuts profit forecast as new CEO faces rocky start
03:04am, Wednesday, 05'th Nov 2025
Novo Nordisk lowered its full-year profit forecast on Wednesday, marking an early challenge for newly appointed CEO Mike Doustdar as the Danish drugmaker grapples with slowing sales and a fast-changin
Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster Drugs
02:24am, Wednesday, 05'th Nov 2025
Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
01:47am, Wednesday, 05'th Nov 2025
A slew of headwinds has shaken investor confidence in what was once Europe's most valuable firm. Novo Nordisk is currently locked in a bidding war with Pfizer for U.S. biotech firm Metsera.
Novo Nordisk Q3 sales beat forecasts in new CEO's maiden quarter
01:38am, Wednesday, 05'th Nov 2025
Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a boost to the Danish drugmaker's new CEO amid a deep restructuring drive to claw back lost grou
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
01:30am, Wednesday, 05'th Nov 2025
Bagsværd, 5 November, 2025 - Financial report for the period 1 January 2025 to 30 September 2025 �
